Outlook Therapeutics Inc (NASDAQ:OTLK) price on Wednesday, March 27, rose 7.95% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.37.
A look at the stock’s price movement, the close in the last trading session was $8.68. The beta value (5-Year monthly) was -0.00. Turning to its 52-week performance, $40.60 and $4.00 were the 52-week high and 52-week low respectively. Overall, OTLK moved 5.78% over the past month.
Outlook Therapeutics Inc’s market cap currently stands at around $121.90 million, with investors looking forward to this quarter’s earnings report slated for May 13, 2024 – May 17, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.85, which has seen fiscal year 2024 EPS growth forecast to increase to -$3.28 and about -$2.02 for fiscal year 2025. Per the data, EPS growth is expected to be 31.70% for 2024 and 38.40% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that OTLK is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
OTLK’s current price about 19.91% and 16.36% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.36, while 7-day volatility ratio is 20.35% and 16.69% in the 30-day chart. Further, Outlook Therapeutics Inc (OTLK) has a beta value of 0.00, and an average true range (ATR) of 1.32.
If we refocus on Outlook Therapeutics Inc (NASDAQ:OTLK), historical trading data shows that trading volumes averaged 2.77 million over the past 10 days and 517.37K over the past 3 months. The company’s latest data on shares outstanding shows there are 13.01 million shares.
The 43.14% of Outlook Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 11.47% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.58 million on Feb 29, 2024, giving us a short ratio of 7.6. The data shows that as of Feb 29, 2024 short interest in Outlook Therapeutics Inc (OTLK) stood at 0.22% of shares outstanding, with shares short falling to 0.68 million registered in Jan 31, 2024. Current price change has pushed the stock 18.91% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the OTLK stock continues to rise going into the next quarter.